CEO SUMMARY: Armed with FDA premarket approval, Cytyc must now overcome significant obstacles to introduce its ThinPrep Pap smear system into widespread clinical usage.
ANOTHER WELL-FINANCED competitor will soon enter the Pap smear marketplace. Cytyc Corporation is offering 3,000,000 shares to the public with the goal of raising $48.2 million.
Cytyc will use $25 million of the
Subscriber-Only Content. Please Log In.
You are trying to access subscribers-only content. If you are a subscriber, please log in.
If you are not a subscriber, click here to see subscription offers.
Subscribers will have instant access to the Dark Report library, 1997-the present, giving you the most convenient, accessible archive available in laboratory business intelligence today!
To read our FREE article previews, go to The Dark Report Insider.